Area of research
Immunology · Infectious Diseases
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, T-cell and B-cell Immunology, and Immunotherapy and Immune Responses.
Affinity maturation of antibody responses is mediated by differential plasma cell proliferation
Epigenetic memory of coronavirus infection in innate immune cells and their progenitors
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals
Role of affinity in plasma cell development in the germinal center light zone
Continually recruited naïve T cells contribute to the follicular helper and regulatory T cell pools in germinal centers
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Prolonged viral suppression with anti-HIV-1 antibody therapy
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
Distinct gene expression by expanded clones of quiescent memory CD4+ T cells harboring intact latent HIV-1 proviruses
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans
Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
Evolution of antibody immunity to SARS-CoV-2
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Dynamic regulation of TFH selection during the germinal centre reaction
Germinal center–dependent and –independent memory B cells produced throughout the immune response
Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence
Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir
Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA